Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant plus nab-paclitaxel in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
2018-004186-14Phase 2Completed
- Sponsor
- Corcept Therapeutics
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of relacorilant and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Corcept Therapeutics. Primary endpoint: Progression-free survival. Started May 2019; status: completed.
02
Drugs
relacorilantpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2018-004186-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004186-14.